{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Malignancy&page=4", "query": { "condition": "Hematologic Malignancy", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 7767, "total_pages": 777, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Malignancy&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematologic+Malignancy&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T07:26:15.478Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00039130", "title": "Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "Allopurinol", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 105, "start_date": "2002-05", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-10-20T07:26:15.478Z", "location_count": 31, "location_summary": "San Diego, California • Lewes, Delaware • Newark, Delaware + 25 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039130" }, { "nct_id": "NCT00379587", "title": "Rituximab for Prevention of Chronic GVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematological Malignancies" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "375 mg/m2 RRituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2006-09", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-03-19", "last_synced_at": "2026-10-20T07:26:15.478Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379587" }, { "nct_id": "NCT03989414", "title": "A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CC-92480", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 424, "start_date": "2019-09-30", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-10-20T07:26:15.478Z", "location_count": 16, "location_summary": "Denver, Colorado • Tampa, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03989414" }, { "nct_id": "NCT05397132", "title": "Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Malignancy" ], "interventions": [ { "name": "Blood draw", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2022-05-27", "completion_date": "2026-02-26", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-20T07:26:15.478Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05397132" }, { "nct_id": "NCT05768932", "title": "BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "TNBC - Triple-Negative Breast Cancer", "Gastric Cancer", "Leukemia Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "BAL0891", "type": "DRUG" }, { "name": "Tislelizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Paclitaxel", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "SillaJen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2022-12-14", "completion_date": "2026-12-24", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-20T07:26:15.478Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768932" }, { "nct_id": "NCT00050687", "title": "Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostatic Neoplasms", "Multiple Myeloma", "Bladder Neoplasms", "Lymphoma" ], "interventions": [ { "name": "Gallium maltolate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Titan Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-06", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2011-01-28", "last_synced_at": "2026-10-20T07:26:15.478Z", "location_count": 5, "location_summary": "Springdale, Arkansas • Greenbrae, California • Palo Alto, California + 2 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Greenbrae", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Southfield", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00050687" }, { "nct_id": "NCT01882387", "title": "Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "TXA127", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tarix Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-12", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2016-08-31", "last_synced_at": "2026-10-20T07:26:15.478Z", "location_count": 2, "location_summary": "Atlanta, Georgia • St Louis, Missouri", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01882387" }, { "nct_id": "NCT04150887", "title": "Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Cusatuzumab", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoVerity, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-12-23", "completion_date": "2027-05-15", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-20T07:26:15.478Z", "location_count": 11, "location_summary": "Duarte, California • Louisville, Kentucky • Detroit, Michigan + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04150887" }, { "nct_id": "NCT06960993", "title": "Mosaic Trial for Stem Cell Transplant Recipients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Malignancy", "Stem Cell Transplant", "Bone Marrow Transplant", "Leukemia", "Lymphoma", "Multiple Myeloma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Intervention website", "type": "BEHAVIORAL" }, { "name": "Enhanced Usual Care (Control) Website", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 356, "start_date": "2025-04-28", "completion_date": "2030-02-01", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-20T07:26:15.478Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Nutley, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Nutley", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06960993" }, { "nct_id": "NCT05611216", "title": "Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloid Leukemia" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 164, "start_date": "2020-12-01", "completion_date": "2021-12-23", "has_results": false, "last_update_posted_date": "2023-04-06", "last_synced_at": "2026-10-20T07:26:15.478Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05611216" } ] }